Alteri Wealth LLC Has $236,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Key Points

• Alteri Wealth LLC has cut its position in Zoetis Inc. by 57.0%, now holding 1,435 shares valued at $236,000 according to its latest SEC filing.
• Geode Capital Management increased its holdings in Zoetis by 1.8% during the fourth quarter, while Wellington Management Group saw a significant 78.5% growth in their stake.
• Zoetis recently announced a quarterly dividend of $0.50 per share, with a yield of 1.32%, reflecting a payout ratio of 35.91%.

Alteri Wealth LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 57.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,435 shares of the company's stock after selling 1,903 shares during the period. Alteri Wealth LLC's holdings in Zoetis were worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in shares of Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Sarasin & Partners LLP purchased a new position in shares of Zoetis during the first quarter worth $339,111,000. GAMMA Investing LLC raised its holdings in shares of Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after purchasing an additional 1,747,423 shares during the last quarter. Capital Research Global Investors purchased a new position in shares of Zoetis during the fourth quarter worth $178,688,000. Finally, Northern Trust Corp raised its holdings in shares of Zoetis by 13.3% during the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock worth $1,047,052,000 after purchasing an additional 755,893 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS traded down $1.74 during midday trading on Thursday, hitting $147.07. 1,858,686 shares of the stock traded hands, compared to its average volume of 3,038,812. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The business's 50 day moving average price is $159.14 and its two-hundred day moving average price is $160.72. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The firm has a market capitalization of $65.48 billion, a PE ratio of 26.39, a price-to-earnings-growth ratio of 2.50 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the previous year, the company earned $1.38 EPS. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.36%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $204.63.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.